SRR934782
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.680
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.665
- IL6_JAK_STAT3_SIGNALING+0.583
- INTERFERON_GAMMA_RESPONSE+0.581
- TNFA_SIGNALING_VIA_NFKB+0.548
- INTERFERON_ALPHA_RESPONSE+0.539
- ALLOGRAFT_REJECTION+0.536
- IL2_STAT5_SIGNALING+0.503
- TGF_BETA_SIGNALING+0.496
- INFLAMMATORY_RESPONSE+0.492
Top 10 suppressed
- KRAS_SIGNALING_DN-0.449
- SPERMATOGENESIS-0.321
- PANCREAS_BETA_CELLS-0.316
- OXIDATIVE_PHOSPHORYLATION-0.153
- BILE_ACID_METABOLISM-0.111
- HEDGEHOG_SIGNALING+0.035
- ESTROGEN_RESPONSE_LATE+0.053
- PEROXISOME+0.067
- FATTY_ACID_METABOLISM+0.075
- MYOGENESIS+0.111
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR934845 | — | — | 0.985 |
| 2 | SRR934952 | — | — | 0.984 |
| 3 | SRR934750 | — | — | 0.984 |
| 4 | 18D7DFBC-A1C6-4DA8-9AF1-3A6F3E2A03BE | — | — | 0.978 |
| 5 | SRR934816 | — | — | 0.977 |
| 6 | 113D7756-712E-4EB4-9993-BBAF3C41AFEF | — | — | 0.974 |
| 7 | SRR934829 | — | — | 0.973 |
| 8 | SRR934987 | — | — | 0.972 |
| 9 | E9FC1686-028B-476C-B51B-4956213D874B | — | — | 0.970 |
| 10 | SRR934913 | — | — | 0.967 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 45 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.680 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.665 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.583 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.581 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.548 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.539 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.536 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.503 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.496 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.492 | Idelalisib | — uncovered |
| APOPTOSIS | 0.471 | Idelalisib | — uncovered |
| COMPLEMENT | 0.471 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.440 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.436 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.436 | Idelalisib | — uncovered |
| G2M_CHECKPOINT | 0.432 | Inavolisib | — uncovered |
| COAGULATION | 0.415 | Binimetinib | — uncovered |
| MTORC1_SIGNALING | 0.415 | Inavolisib | — uncovered |
| HYPOXIA | 0.410 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.381 | Inavolisib | — uncovered |